Claims for Patent: 7,651,698

Summary for Patent: 7,651,698

Title:	Prolonged release bioadhesive therapeutic systems
Abstract:	The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. This bioadhesive therapeutic system comprises quantities of natural proteins representing 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.
Inventor(s):	Aiache; Jean-Marc (Paris, FR), Costantini; Dominique (Paris, FR), Chaumont; Christine (Paris, FR)
Assignee:	Bioalliance Pharma (Paris, FR)
Application Number:	11/113,072
Patent Claims:	1. A method for treating buccal candidiasis which comprises administering to a patient in need thereof, a bioadhesive therapeutic system containing at least one active principle, having an active principle dissolution percentage of more than 70% over 8 hours, comprising quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said bioadhesive therapeutic system, between 10% and 20% of a hydrophilic polymer, compression excipients, and comprising between 3.5% and 10% of an alkali metal alkylsulphate and between 0.1% and 1% of a monohydrate sugar, wherein said active principle is an antifungal from the broad spectrum azole family. 2. The method of claim 1, wherein the alkali metal alkylsulphate is sodium laurylsulphate or diethylsulphosuccinate. 3. The method of claim 1, in the form of a tablet in which the alkylsulphate is sodium laurylsulphate in a concentration of 3.5% to 10% of the total weight of the compounds in the tablet. 4. The method of claim 1, in which the sugar monohydrate is lactose monohydrate or saccharose. 5. The method according to claim 1, wherein the compression excipients contain corn starch. 6. The method of claim 1, in which the antifungal from the broad spectrum azole family is selected from the group consisting of miconazole, clotrimazole, ketoconazole, fluconazole, itraconazole, isoconazole, econazole, saperconazole, genaconazole, terconazole, butoconazole, tioconazole, oxiconazole, bifonazole, fenticonazole, omoconazole, sertaconazole and sulconazole. 7. The method according to claim 6, in which the azole is micoazole present in a dose of 10 to 150 mg per bioadhesive therapeutic system. 8. The method according to claim 7, in which the miconazole is present in an amount of 25 to 75 mg per bioadhesive therapeutic system. 9. The method according to claim 7, in which the miconazole is present in an amount of 50 mg per bioadhesive therapeutic system. 10. The method according to claim 3, in which the sodium laurylsulphate is in a concentration of 4% to 6% of the total weight of the compounds in the tablet. 11. A method for treating buccal candidiasis which comprises administering to a patient in need thereof, a bioadhesive therapeutic system containing at least one active principle selected from the group of: miconazole, clotrimazole, ketoconazole, fluconazole, itraconazole, isoconazole, econazole, saperconazole, genaconazole, terconazole, butoconazole, tioconazole, oxiconazole, bifonazole, fenticonazole, omoconazole, sertaconazole and sulconazole, having an active principle dissolution percentage of more than 70% over 8 hours, comprising quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said bio adhesive therapeutic system, between 10% and 20% of a hydrophilic polymer, compression excipients, and comprising between 3.5% and 10% of sodium lauryl sulphate or diethylsulphosuccinate and between 0.1% and 1% of saccharose or lactose monohydrate. 12. A method for treating buccal candidiasis which comprises administering to a patient in need thereof, a bioadhesive therapeutic system containing at least miconazole, having an active principle dissolution percentage of more than 70% over 8 hours, comprising quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said bioadhesive therapeutic system, between 10% and 20% of a hydrophilic polymer, compression excipients, and comprising between 3.5% and 10% of an alkali metal alkylsulphate and between 0.1% and 1% of a monohydrate sugar. 13. The method according to claim 12, wherein the micoazole present in a dose of 10 to 150 mg per bioadhesive therapeutic system. 14. The method according to claim 12, in which the miconazole is present in an amount of 25 to 75 mg per bioadhesive therapeutic system. 15. The method according to claim 12, in which the miconazole is present in an amount of 50 mg per bioadhesive therapeutic system. 16. The method according to claim 12, in which the alkali metal alkylsulphate is sodium laurylsulphate and is present in a concentration of 4% to 6% of the total weight of the compounds in the tablet. 17. A method for treating buccal candidiasis which comprises administering to a patient in need thereof, a bioadhesive therapeutic system containing at least miconazole in an amount of 50 mg per bioadhesive therapeutic system, having an active principle dissolution percentage of more than 70% over 8 hours, comprising quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said bioadhesive therapeutic system, between 10% and 20% of a hydrophilic polymer, compression excipients, and comprising between 3.5% and 10% of sodium laurylsulphate and between 0.1% and 1% of a monohydrate sugar.